WO2006108965A3 - Antagonistes npy, preparation et utilisations - Google Patents

Antagonistes npy, preparation et utilisations Download PDF

Info

Publication number
WO2006108965A3
WO2006108965A3 PCT/FR2006/000829 FR2006000829W WO2006108965A3 WO 2006108965 A3 WO2006108965 A3 WO 2006108965A3 FR 2006000829 W FR2006000829 W FR 2006000829W WO 2006108965 A3 WO2006108965 A3 WO 2006108965A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
npy
preparation
antagonists
therapeutic
Prior art date
Application number
PCT/FR2006/000829
Other languages
English (en)
Other versions
WO2006108965A2 (fr
Inventor
Iuliana Botez
Christelle David-Basei
Nelly Gourlaouen
Eric Nicolai
Fabrice Balavoine
Gerard Valette
Gal Claudine Serradeil-Le
Original Assignee
Cerep
Iuliana Botez
Christelle David-Basei
Nelly Gourlaouen
Eric Nicolai
Fabrice Balavoine
Gerard Valette
Gal Claudine Serradeil-Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008505929A priority Critical patent/JP2008538749A/ja
Priority to MX2007012847A priority patent/MX2007012847A/es
Priority to CA002604773A priority patent/CA2604773A1/fr
Priority to EA200800157A priority patent/EA200800157A1/ru
Priority to EP06743700A priority patent/EP1879887A2/fr
Priority to US11/918,470 priority patent/US20090233910A1/en
Priority to AU2006234413A priority patent/AU2006234413A1/en
Priority to AP2007004218A priority patent/AP2007004218A0/xx
Application filed by Cerep, Iuliana Botez, Christelle David-Basei, Nelly Gourlaouen, Eric Nicolai, Fabrice Balavoine, Gerard Valette, Gal Claudine Serradeil-Le filed Critical Cerep
Publication of WO2006108965A2 publication Critical patent/WO2006108965A2/fr
Publication of WO2006108965A3 publication Critical patent/WO2006108965A3/fr
Priority to TNP2007000376A priority patent/TNSN07376A1/en
Priority to IL186601A priority patent/IL186601A0/en
Priority to NO20075322A priority patent/NO20075322L/no
Priority to EC2007007894A priority patent/ECSP077894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

La présente invention concerne de nouveaux composés, leur préparation et leurs utilisations, notamment thérapeutiques. Elle concerne plus particulièrement des composés dérivés présentant au moins deux cycles aromatiques, leur préparation et leurs utilisations, notamment dans le domaine de la santé humaine ou animale. Ces composés ont une affinité pour les récepteurs biologiques du neuropeptide Y, NPY, présents dans les systèmes nerveux central et périphérique. Les composés selon l'invention sont préférentiellement des antagonistes de NPY et plus particulièrement des antagonistes du sous-type NPY Y1, et sont donc utilisables dans le traitement thérapeutique ou prophylactique de tout désordre impliquant NPY. La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, leur préparation et leurs utilisations, ainsi que des méthodes de traitement utilisant lesdits composés.
PCT/FR2006/000829 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations WO2006108965A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2006234413A AU2006234413A1 (en) 2005-04-15 2006-04-14 NPY antagonists, preparation and use
CA002604773A CA2604773A1 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations
EA200800157A EA200800157A1 (ru) 2005-04-15 2006-04-14 Антагонисты npy, способ их получения и применение
EP06743700A EP1879887A2 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations
US11/918,470 US20090233910A1 (en) 2005-04-15 2006-04-14 Npy antagonists, preparation and uses
JP2008505929A JP2008538749A (ja) 2005-04-15 2006-04-14 Ｎｐｙ拮抗物質、調製および使用
AP2007004218A AP2007004218A0 (en) 2005-04-15 2006-04-14 NPY antagonists, preparation and use
MX2007012847A MX2007012847A (es) 2005-04-15 2006-04-14 Antagonistas de npy, preparacion y usos.
TNP2007000376A TNSN07376A1 (en) 2005-04-15 2007-10-05 Npy antagonists, preparation and use
IL186601A IL186601A0 (en) 2005-04-15 2007-10-11 Npy antagonists, preparation and use
NO20075322A NO20075322L (no) 2005-04-15 2007-10-17 NPY antagonister, samt femstilling og anvendelse av samme
EC2007007894A ECSP077894A (es) 2005-04-15 2007-11-13 Antagonistas de npy, preparación y usos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503795A FR2884516B1 (fr) 2005-04-15 2005-04-15 Antagonistes npy, preparation et utilisations
FR0503795 2005-04-15

Publications (2)

Publication Number Publication Date
WO2006108965A2 WO2006108965A2 (fr) 2006-10-19
WO2006108965A3 true WO2006108965A3 (fr) 2007-03-29

Family

ID=35447654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000829 WO2006108965A2 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations

Country Status (19)

Country Link
US (1) US20090233910A1 (fr)
EP (1) EP1879887A2 (fr)
JP (1) JP2008538749A (fr)
KR (1) KR20080009112A (fr)
CN (1) CN101198604A (fr)
AP (1) AP2007004218A0 (fr)
AU (1) AU2006234413A1 (fr)
CA (1) CA2604773A1 (fr)
CR (1) CR9514A (fr)
EA (1) EA200800157A1 (fr)
EC (1) ECSP077894A (fr)
FR (1) FR2884516B1 (fr)
IL (1) IL186601A0 (fr)
MA (1) MA29444B1 (fr)
MX (1) MX2007012847A (fr)
NI (1) NI200700260A (fr)
NO (1) NO20075322L (fr)
TN (1) TNSN07376A1 (fr)
WO (1) WO2006108965A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
WO2007070173A2 (fr) * 2005-10-31 2007-06-21 Merck & Co., Inc. Inhibiteurs de la cetp
US7816535B2 (en) 2006-01-25 2010-10-19 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
CA2674237C (fr) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. Composes d'heterocycloalkyloxybenzamide n-substitues, et procedes d'utilisation
JP2010527915A (ja) * 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
JP2008303155A (ja) * 2007-06-06 2008-12-18 Ube Ind Ltd Ｎ−（ω−フルオロアルキル）環状アミン化合物の製法、並びに新規なＮ−（４−フルオロブチル）環状アミン化合物及びその製法
JP2009035537A (ja) * 2007-07-10 2009-02-19 Nippon Synthetic Chem Ind Co Ltd:The Ｎ−置換アニリン誘導体及び１−置換インドール誘導体の製造方法
WO2010036908A1 (fr) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Utilisation de composés benzoxazole dans le traitement du paludisme
US20110230497A1 (en) * 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
EP2519517B1 (fr) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
AU2013212209A1 (en) * 2012-01-25 2014-06-26 Demerx, Inc. (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
WO2015177193A1 (fr) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Composés stabilisants
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016187667A1 (fr) * 2015-05-27 2016-12-01 Novogen Limited Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux
EP4019515A1 (fr) * 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
JP2017137259A (ja) * 2016-02-03 2017-08-10 株式会社Ihi 有機化合物の製造方法
CN109071542B (zh) 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
CN106543089A (zh) * 2016-11-04 2017-03-29 山东铂源药业有限公司 一种达沙替尼中间体的合成方法
CN107892656A (zh) * 2017-10-27 2018-04-10 苏州盖德精细材料有限公司 一种2,5‑二氨基苯乙醇的制备方法
KR20220100858A (ko) * 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
KR102234530B1 (ko) * 2020-09-01 2021-03-31 대한민국 신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN117003672A (zh) * 2023-08-09 2023-11-07 湖南正量工程技术有限公司 一种boc-4，4'-二硝基二苯胺的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064394A1 (fr) * 1998-06-08 1999-12-16 Schering Corporation Antagonistes des recepteurs y5 neuropeptidiques
WO2000068201A1 (fr) * 1999-05-08 2000-11-16 Astrazeneca Ab Derives quinoline inhibiteurs d'enzymes mek
WO2003009845A1 (fr) * 2001-07-26 2003-02-06 Schering Corporation Antagonistes du recepteur y5 du neuropeptide y d'uree substituee
US20030027862A1 (en) * 2000-08-04 2003-02-06 Helmut Haning Amino-and amido-diphenyl ethers
WO2003072577A1 (fr) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
WO2004110368A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie pour le traitement de l'hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06248153A (ja) * 1993-03-01 1994-09-06 Shin Etsu Chem Co Ltd 難燃樹脂組成物
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
JP2000287697A (ja) * 1999-02-05 2000-10-17 Shionogi & Co Ltd Ｎｐｙ受容体親和性を有するラクトン誘導体
EP1322628A2 (fr) * 2000-09-14 2003-07-02 Schering Corporation Antagonistes du recepteur y.y5 de neuropeptide d'urease substitue
WO2004007437A1 (fr) * 2002-07-11 2004-01-22 Aventis Pharma Deutschland Gmbh Acylurees substituees par uree et urethane, procedes permettant de les produire et leur utilisation comme medicaments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064394A1 (fr) * 1998-06-08 1999-12-16 Schering Corporation Antagonistes des recepteurs y5 neuropeptidiques
WO2000068201A1 (fr) * 1999-05-08 2000-11-16 Astrazeneca Ab Derives quinoline inhibiteurs d'enzymes mek
US20030027862A1 (en) * 2000-08-04 2003-02-06 Helmut Haning Amino-and amido-diphenyl ethers
WO2003009845A1 (fr) * 2001-07-26 2003-02-06 Schering Corporation Antagonistes du recepteur y5 du neuropeptide y d'uree substituee
WO2003072577A1 (fr) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
WO2004110368A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie pour le traitement de l'hypertension

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9365563B2 (en) 2007-04-27 2016-06-14 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Also Published As

Publication number Publication date
KR20080009112A (ko) 2008-01-24
ECSP077894A (es) 2008-03-26
TNSN07376A1 (en) 2009-03-17
NO20075322L (no) 2008-01-11
EP1879887A2 (fr) 2008-01-23
EA200800157A1 (ru) 2008-04-28
FR2884516B1 (fr) 2007-06-22
AU2006234413A1 (en) 2006-10-19
AP2007004218A0 (en) 2007-10-31
CR9514A (es) 2008-08-26
CN101198604A (zh) 2008-06-11
IL186601A0 (en) 2008-01-20
NI200700260A (es) 2009-03-03
CA2604773A1 (fr) 2006-10-19
US20090233910A1 (en) 2009-09-17
FR2884516A1 (fr) 2006-10-20
MA29444B1 (fr) 2008-05-02
JP2008538749A (ja) 2008-11-06
MX2007012847A (es) 2008-03-25
WO2006108965A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006108965A3 (fr) Antagonistes npy, preparation et utilisations
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2007025069A3 (fr) Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
EP2305640A3 (fr) Diphenyl-éthers, -amines, -sulfides et -méthanes pour le traitement de maladies respiratoires
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2006058868A8 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
WO2005072308A3 (fr) Antagonistes des recepteurs du cgrp
WO2007019234A3 (fr) Antagonistes des recepteurs d'orexine a base de sulfamide d'aminoethane
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
TW200611695A (en) Pyrrolopyridine derivatives
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
WO2007067511A3 (fr) Antagonistes de recepteur de prokineticine de morpholine-carboxamide
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
WO2007058805A3 (fr) Compositions et procedes destines au traitement des troubles du snc
WO2006069808A3 (fr) Composes de phenyl-piperazine a substitution nitro, leur preparation et leur utilisation dans des medicaments
WO2007071840A3 (fr) Composes a base de quatre cycles aromatiques, preparation et utilisations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2604773

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 186601

Country of ref document: IL

Ref document number: 12007502255

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012847

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008505929

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 562774

Country of ref document: NZ

Ref document number: 8214/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006743700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004218

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: DZP2007000670

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2006234413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077026216

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 07119362

Country of ref document: CO

Ref document number: CR2007-009514

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007142180

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006234413

Country of ref document: AU

Date of ref document: 20060414

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006234413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680021275.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006743700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800157

Country of ref document: EA

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0608778

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL, TENDO EM VISTA A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL, EM FACE DA NAO APRESENTACAO DE PELO MENOS UM QUADRO REIVINDICATORIO TRADUZIDO, CONFORME ATO NORMATIVO NO 128, DE 05/03/1997, ITEM 9.2, CABENDO DESARQUIVAMENTO

WWE Wipo information: entry into national phase

Ref document number: 11918470

Country of ref document: US